The gut microbiome constitutes a complex and metabolically active ecosystem that exerts profound effects on host physiology through the production of diverse small-molecule metabolites. Increasing evidence indicates that microbiome-derived metabolites function as a critical bridge linking microbial dysbiosis with tumor initiation, progression, immune modulation, and therapeutic responsiveness. Alterations in microbial metabolic outputs, including short-chain fatty acids, secondary bile acids, po